FDA Panel Deems Non-inferiority Trials For J&J’s Doribax Inferior

FDA’s Anti-Infective Drugs Advisory votes 10-3 that a 20 percent non-inferiority margin for the antibiotic is not scientifically justifiable.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet